Source comparison
Women 45-55 Perimenopause Kisspeptin Protocol: Study Comparison
Imperial College London 2024 (JCEM) 82 women, 45-54 years, ≥7 hot flashes/day Kisspeptin-54, 1.5 nmol/kg, 3×/week 12 weeks Hot flash frequency reduction 43% reduction vs 12% placebo by week 8 Strongest evidence for vasomotor symptom control. Subcutaneous route
This comparison does not assign a generated winner or score.
- Imperial College London 2024 (JCEM)
- 82 women, 45-54 years, ≥7 hot flashes/day
- Kisspeptin-54, 1.5 nmol/kg, 3×/week
- 12 weeks
- Hot flash frequency reduction
- 43% reduction vs 12% placebo by week 8
- Strongest evidence for vasomotor symptom control. Subcutaneous route validated
- Cambridge 2023
- 64 women, 47-53 years, irregular cycles
- Kisspeptin-10, 1 nmol/kg, 2×/week
- 16 weeks
- Menstrual cycle regularity (24-35 day intervals)
- 68% achieved regular cycles; 59% ovulatory vs 31% baseline
- Best data for cycle restoration. Demonstrates HPG axis retraining rather than replacement
- NIH 2022 Pilot
- 28 women, 46-52 years, sleep disruption
- Kisspeptin-54, 2 nmol/kg, 3×/week
- 8 weeks
- Objective sleep efficiency (actigraphy)
- 38% improvement in total sleep time; reduced nocturnal awakenings by 29%
- Sleep outcomes tied to reduced LH surge variability. Indirect vasomotor stabilisation